
<DOC>
<DOCNO>
WSJ900809-0042
</DOCNO>
<DOCID>
900809-0042.
</DOCID>
<HL>
   Corrections &amp; Amplifications
</HL>
<DATE>
08/09/90
</DATE>
<SO>
WALL STREET JOURNAL (J), PAGE A4
</SO>
<LP>
   MERCK &amp; Co. has proposed a plan for drugs sold to Medicaid
with price discounts of 10% to 15% in the first two years and
10% to 25% in the fifth year, and the discounts would be
granted by all drug companies, not just Merck. The details of
the Merck plan were misstated in yesterday's edition.
   (See: "Medicine: Drug Concerns Seek to Block Medicaid
Curbs" -- WSJ Aug. 8, 1990)
</LP>
<TEXT>
   ---
   A SYNTRO CORP. EXECUTIVE, clarifying statements he made in
yesterday's edition, said the company expects to be operating
at a break-even level Sept. 30, the end of its fiscal year,
but still expects to report a net loss for the year. Further,
he said the company has a 40% share of the U.S. market for
its swine vaccine. Also, the company had a $1.6 million loss
for the nine months ended June 30. The amount of the loss was
misstated in yesterday's edition.
   (See: "Business Brief -- Syntro Corp.: Firm, Upjohn Settle
Suits on Swine Vaccine Patents" -- WSJ Aug. 8, 1990)
</TEXT>
</DOC>